Posted 10 Jan 2024

A small, but well-conducted, study of the effect of CBD oil on bad toothaches neither proves nor disproves whether the drug works. However, some intriguing data could be confirmed in a larger clinical trial. Let’s call this mildly encouraging. At best.

I’m always skeptical of claims concerning therapeutic uses of CBD oil (cannabidiol) and also the results of clinical trials that contain a small number of participants. So when I came across a 2023 paper in the Journal of Dental Research (peer-reviewed) about a clinical trial with 61 participants that examined whether CBD could be used to treat toothache pain, I was tempted to ignore it. But the trial by the Rutgers School of Dental Medicine should not be ignored; it was a double-blinded placebo-controlled randomized clinical trial (RCT) with two different doses

Read the rest

Cannabidiol promoters warned

Posted 10 April 2019

The Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) have jointly sent warning letters to Nutra Pure LLC, PotNetwork Holdings, Inc., and Advanced Spine and Pain, LLC (d/b/a Relievus) because they believe the companies are illegally marketing products containing cannabidiol (CBD) to treat a variety of serious diseases and conditions.

[FTC joins FDA in sending warning letters to companies advertising and selling products containing cannabidiol (CBD) claiming to treat Alzheimer’s, cancer, and other diseases. FTC Press Release. April 2, 2019]

CBD is a chemical compound found in marijuana and hemp that does not produce a high. In 2018, the FDA approved a cannabidiol preparation (brand name Epidiolex) to treat two rare, severe forms of epilepsy. But since 2015, the FDA has ordered many companies to stop making unapproved claims.

The market for unapproved CBD products is nevertheless burgeoning, as consumer Read the rest

Status of cannabis-containing products (including oils) and the cultivation of cannabis for medicinal use

Posted 06 February 2019

This communication to stakeholders has been placed on the SAHPRA web site and should provide much-needed clarity on the legal status of the many cannabis-containing products that are currently on the South African market, but also on the use of the section 21 process for access to quality-assured medicinal products.

Status of cannabis-containing products (including oils) and the cultivation of cannabis for medicinal use


On the 18th September 2018 the Constitutional Court handed down a judgment1, which declared existing legislation, criminalising the use, possession, and cultivation of cannabis, unconstitutional. It would, therefore, now not be an offence for an adult person to:

  1. use or be in possession of cannabis in private for his or her personal consumption in private; and b. to cultivate cannabis in a private place for his or her personal consumption in private.

The Court also found section 22A(9)(a)(i) of Read the rest

Cannabis health products are everywhere – but do they live up to the hype?

Posted 17 October 2018

Cannabidiol, or CBD, is now available in the UK in everything from skin creams to beers. But don’t set your hopes too high

Amy Fleming Mon 15 Oct 2018 The Guardian

This has been the year medical cannabis hit the mainstream. The government has announced that it is relaxing laws on when cannabis medicines can be prescribed by doctors, following high-profile cases such as that of Billy Caldwell, the 13-year-old boy hospitalised by his epileptic seizures after he was denied legal access to the cannabis oil that helps control them. Meanwhile a new generation of cannabis medicines has shown great promise (both anecdotally and in early clinical trials) in treating a range of ills from anxiety, psychosis and epilepsy to pain, inflammation and acne. And you don’t have to get stoned to reap the health benefits.

Read the rest

Medicinal cannabis products: Patient information

Posted 30 May 2018

The Australian TGA (Therapeutic Goods Administration) has published the following patient information guide.

In South Africa, an application in terms of s22A(9) is needed for exceptional access to THC-containing preparations for research or treatment, and a s21 application needed for access to unregistered THC (S6 when intended for therapeutic purposes) or CBD (S4 when intended for therapeutic purposes) preparations. 

Medicinal cannabis products: Patient information

29 May 2018               

Over the past few years there has been increased interest from Australians in the use of cannabis for medicinal purposes. Commonwealth, state and territory governments have used existing laws or passed specific laws to allow the prescribing and dispensing of medicinal cannabis products, as well as cannabis cultivation and manufacture for medicinal purposes.

Read the rest

FDA Pursues Unproven Cancer Claims

Posted 21 December 2017

December 19, 2017

FDA Pursues Unproven Cancer Claims

Rebecca Voelker, MSJ

JAMA.  2017;318(23):2288. doi:10.1001/jama.2017.19150

Four companies have received FDA warning letters for selling products online that agency officials said made unproven anticancer claims and contained a component of the marijuana plant.

The products reportedly contained cannabidiol (CBD), which isn’t FDA approved for any indication. Such products are marketed in a variety of forms including oil drops, capsules, syrup, tea, and topical lotion or cream. Selling unapproved products with unsubstantiated therapeutic claims violates the federal Food, Drug, and Cosmetic Act and could harm patients, according to FDA officials.

Claims made on web pages, online stores, and social media touted the products’ abilities to combat tumor and cancer cells, make cancer cells “commit suicide” without killing other cells, and inhibit cell division and growth in certain types of cancer. Some of the products also were marketed as alternative Read the rest